{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:17:16Z","timestamp":1787008636118,"version":"build-2736575974"},"reference-count":36,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2019,5,16]],"date-time":"2019-05-16T00:00:00Z","timestamp":1557964800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100000030","name":"CDC","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000030","id-type":"DOI","asserted-by":"publisher"}]},{"name":"National Center for HIV"},{"name":"Viral Hepatitis"},{"name":"STD, and TB Prevention Epidemiologic and Economic Modeling Agreement","award":["5NU38PS004644"],"award-info":[{"award-number":["5NU38PS004644"]}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["K23 DA044085-01"],"award-info":[{"award-number":["K23 DA044085-01"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["R01DA046527"],"award-info":[{"award-number":["R01DA046527"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["P30 DA040500"],"award-info":[{"award-number":["P30 DA040500"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["5P30AI042853-18"],"award-info":[{"award-number":["5P30AI042853-18"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,3,17]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Hepatitis C virus (HCV) testing and treatment uptake in prisons remains low. We aimed to estimate clinical outcomes, cost-effectiveness (CE), and budgetary impact (BI) of HCV testing and treatment in United States (US) prisons or linkage to care at release.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We used individual-based simulation modeling with healthcare and Department of Corrections (DOC) perspectives for CE and BI analyses, respectively. We simulated a US prison cohort at entry using published data and Washington State DOC individual-level data. We considered permutations of testing (risk factor based, routine at entry or at release, no testing), treatment (if liver fibrosis stage \u2265F3, for all HCV infected or no treatment), and linkage to care (at release or no linkage). Outcomes included quality-adjusted life-years (QALY); cases identified, treated, and cured; cirrhosis cases avoided; incremental cost-effectiveness ratios; DOC costs (2016 US dollars); and BI (healthcare cost\/prison entrant) to generalize to other states.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Compared to \u201cno testing, no treatment, and no linkage to care,\u201d the \u201ctest all, treat all, and linkage to care at release\u201d model increased the lifetime sustained virologic response by 23%, reduced cirrhosis cases by 54% at a DOC annual additional cost of $1440 per prison entrant, and would be cost-effective. At current drug prices, targeted testing and liver fibrosis\u2013based treatment provided worse outcomes at higher cost or worse outcomes at higher cost per QALY gained. In sensitivity analysis, fibrosis-based treatment restrictions were cost-effective at previous higher drug costs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Although costly, widespread testing and treatment in prisons is considered to be of good value at current drug prices.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/cid\/ciz383","type":"journal-article","created":{"date-parts":[[2019,5,15]],"date-time":"2019-05-15T07:10:43Z","timestamp":1557904243000},"page":"1388-1396","source":"Crossref","is-referenced-by-count":26,"title":["Cost-effectiveness and Budgetary Impact of Hepatitis C Virus Testing, Treatment, and Linkage to Care in US Prisons"],"prefix":"10.1093","volume":"70","author":[{"given":"Sabrina A","family":"Assoumou","sequence":"first","affiliation":[{"name":"Section of Infectious Disease, Department of Medicine, Boston Medical Center, Massachusetts"},{"name":"Section of Infectious Disease, Department of Medicine, Boston University School of Medicine, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abriana","family":"Tasillo","sequence":"first","affiliation":[{"name":"Section of Infectious Disease, Department of Medicine, Boston Medical Center, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Vellozzi","sequence":"first","affiliation":[{"name":"Grady Health System, Centers for Disease Control and Prevention, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Golnaz","family":"Eftekhari Yazdi","sequence":"first","affiliation":[{"name":"Section of Infectious Disease, Department of Medicine, Boston Medical Center, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianing","family":"Wang","sequence":"first","affiliation":[{"name":"Section of Infectious Disease, Department of Medicine, Boston Medical Center, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shayla","family":"Nolen","sequence":"first","affiliation":[{"name":"Section of Infectious Disease, Department of Medicine, Boston Medical Center, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liesl","family":"Hagan","sequence":"first","affiliation":[{"name":"Prevention Branch, Division of Viral Hepatitis, Centers for Disease Control and Prevention, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Thompson","sequence":"first","affiliation":[{"name":"Prevention Branch, Division of Viral Hepatitis, Centers for Disease Control and Prevention, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liisa M","family":"Randall","sequence":"first","affiliation":[{"name":"Massachusetts Department of Public Health, Boston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lara","family":"Strick","sequence":"first","affiliation":[{"name":"Division of Allergy and Infectious Diseases, Department of Medicine, University of Washington, Seattle"},{"name":"Washington State Department of Corrections, Tumwater"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua A","family":"Salomon","sequence":"first","affiliation":[{"name":"Stanford University School of Medicine, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin P","family":"Linas","sequence":"first","affiliation":[{"name":"Section of Infectious Disease, Department of Medicine, Boston Medical Center, Massachusetts"},{"name":"Section of Infectious Disease, Department of Medicine, Boston University School of Medicine, Massachusetts"},{"name":"Department of Epidemiology, Boston University School of Public Health, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,5,16]]},"reference":[{"key":"2020062607534775800_CIT0001","first-page":"27","article-title":"Impact of new therapeutics for hepatitis C virus infection in incarcerated populations","volume":"21","author":"Spaulding","year":"2013","journal-title":"Top Antivir Med"},{"key":"2020062607534775800_CIT0002","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1177\/003335491412900213","article-title":"Hepatitis C seroprevalence among prison inmates since 2001: still high but declining","volume":"129","author":"Varan","year":"2014","journal-title":"Public Health Rep"},{"key":"2020062607534775800_CIT0003","doi-asserted-by":"crossref","first-page":"84","DOI":"10.7326\/M15-0617","article-title":"Prevention of hepatitis C by screening and treatment in U.S. prisons","volume":"164","author":"He","year":"2016","journal-title":"Ann Intern Med"},{"key":"2020062607534775800_CIT0004","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1002\/hep.22509","article-title":"Treating hepatitis C in the prison population is cost-saving","volume":"48","author":"Tan","year":"2008","journal-title":"Hepatology"},{"key":"2020062607534775800_CIT0005","doi-asserted-by":"crossref","first-page":"546","DOI":"10.7326\/M14-0602","article-title":"Sofosbuvir-based treatment regimens for chronic, genotype 1 hepatitis C virus infection in U.S. incarcerated populations: a cost-effectiveness analysis","volume":"161","author":"Liu","year":"2014","journal-title":"Ann Intern Med"},{"key":"2020062607534775800_CIT0006","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1093\/cid\/cix798","article-title":"The cost-effectiveness of one-time hepatitis C screening strategies among adolescents and young adults in primary care settings","volume":"66","author":"Assoumou","year":"2018","journal-title":"Clin Infect Dis"},{"key":"2020062607534775800_CIT0007","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1097\/QAD.0000000000000093","article-title":"The cost-effectiveness of improved hepatitis C virus therapies in HIV\/hepatitis C virus coinfected patients","volume":"28","author":"Linas","year":"2014","journal-title":"AIDS"},{"key":"2020062607534775800_CIT0008","doi-asserted-by":"crossref","first-page":"619","DOI":"10.7326\/M14-1313","article-title":"The cost-effectiveness of sofosbuvir-based regimens for treatment of hepatitis C virus genotype 2 or 3 infection","volume":"162","author":"Linas","year":"2015","journal-title":"Ann Intern Med"},{"key":"2020062607534775800_CIT0009","doi-asserted-by":"crossref","first-page":"e97317","DOI":"10.1371\/journal.pone.0097317","article-title":"The hepatitis C cascade of care: identifying priorities to improve clinical outcomes","volume":"9","author":"Linas","year":"2014","journal-title":"PLoS One"},{"key":"2020062607534775800_CIT0010","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1002\/hep.24105","article-title":"Performance of the aspartate aminotransferase-to-platelet ratio index for the staging of hepatitis C-related fibrosis: an updated meta-analysis","volume":"53","author":"Lin","year":"2011","journal-title":"Hepatology"},{"key":"2020062607534775800_CIT0011","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1111\/add.12863","article-title":"Mortality among individuals accessing pharmacological treatment for opioid dependence in California, 2006-10","volume":"110","author":"Evans","year":"2015","journal-title":"Addiction"},{"key":"2020062607534775800_CIT0012","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1038\/ajg.2009.31","article-title":"Predicting mortality risk in patients with compensated HCV-induced cirrhosis: a long-term prospective study","volume":"104","author":"Bruno","year":"2009","journal-title":"Am J Gastroenterol"},{"key":"2020062607534775800_CIT0013","doi-asserted-by":"crossref","first-page":"102","DOI":"10.2471\/BLT.12.108282","article-title":"Mortality among people who inject drugs: a systematic review and meta-analysis","volume":"91","author":"Mathers Bradley","year":"2013","journal-title":"Bull World Health Organ"},{"key":"2020062607534775800_CIT0014","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1093\/aje\/kwg209","article-title":"Longitudinal patterns of drug injection behavior in the ALIVE study cohort, 1988\u20132000: description and determinants","volume":"158","author":"Galai","year":"2003","journal-title":"Am J Epidemiol"},{"key":"2020062607534775800_CIT0015","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1093\/infdis\/jiv220","article-title":"Hepatitis C virus reinfection and spontaneous clearance of reinfection\u2014the InC3 study","volume":"212","author":"Sacks-Davis","year":"2015","journal-title":"J Infect Dis"},{"key":"2020062607534775800_CIT0016","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1111\/j.1365-2893.2005.00651.x","article-title":"Spontaneous viral clearance following acute hepatitis C infection: a systematic review of longitudinal studies","volume":"13","author":"Micallef","year":"2006","journal-title":"J Viral Hepat"},{"key":"2020062607534775800_CIT0017","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.drugalcdep.2014.10.025","article-title":"Trends in use of health care and HIV prevention services for persons who inject drugs in San Francisco: results from National HIV Behavioral Surveillance 2005-2012","volume":"146","author":"Coffin","year":"2015","journal-title":"Drug Alcohol Depend"},{"key":"2020062607534775800_CIT0018","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1002\/hep.27584","article-title":"The continuum of hepatitis C testing and care","volume":"61","author":"Viner","year":"2015","journal-title":"Hepatology"},{"key":"2020062607534775800_CIT0019","doi-asserted-by":"crossref","first-page":"e5","DOI":"10.2105\/AJPH.2015.302635","article-title":"The HIV care cascade before, during, and after incarceration: a systematic review and data synthesis","volume":"105","author":"Iroh","year":"2015","journal-title":"Am J Public Health"},{"key":"2020062607534775800_CIT0020","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/j.drugpo.2015.07.004","article-title":"Hepatitis C virus (HCV) disease progression in people who inject drugs (PWID): a systematic review and meta-analysis","volume":"26","author":"Smith","year":"2015","journal-title":"Int J Drug Policy"},{"key":"2020062607534775800_CIT0021","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1111\/jvh.12506","article-title":"Disparate access to treatment regimens in chronic hepatitis C patients: data from the TRIO network","volume":"23","author":"Younossi","year":"2016","journal-title":"J Viral Hepat"},{"key":"2020062607534775800_CIT0022","doi-asserted-by":"crossref","first-page":"2599","DOI":"10.1056\/NEJMoa1512610","article-title":"Sofosbuvir and velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection","volume":"373","author":"Feld","year":"2015","journal-title":"N Engl J Med"},{"key":"2020062607534775800_CIT0023","author":"Agency for Healthcare Research and Quality"},{"key":"2020062607534775800_CIT0024","doi-asserted-by":"crossref","first-page":"e17","DOI":"10.1097\/MCG.0b013e3181e12c09","article-title":"Direct economic burden of chronic hepatitis C virus in a United States managed care population","volume":"45","author":"Davis","year":"2011","journal-title":"J Clin Gastroenterol"},{"key":"2020062607534775800_CIT0025","author":"Nisen"},{"key":"2020062607534775800_CIT0026","author":"Solutions","year":"2017"},{"key":"2020062607534775800_CIT0027","author":"United States Department of Health and Human Services Center for Medicare Services"},{"key":"2020062607534775800_CIT0028","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1177\/0272989X06290495","article-title":"Preference-based EQ-5D index scores for chronic conditions in the United States","volume":"26","author":"Sullivan","year":"2006","journal-title":"Med Decis Making"},{"key":"2020062607534775800_CIT0029","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1177\/0272989X08315240","article-title":"Health-state utilities in liver disease: a systematic review","volume":"28","author":"McLernon","year":"2008","journal-title":"Med Decis Making"},{"key":"2020062607534775800_CIT0030","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1111\/jvh.12173","article-title":"The new paradigm of hepatitis C therapy: integration of oral therapies into best practices","volume":"20","author":"Afdhal","year":"2013","journal-title":"J Viral Hepat"},{"key":"2020062607534775800_CIT0031","doi-asserted-by":"crossref","first-page":"345","DOI":"10.7326\/M16-0065","article-title":"Hepatitis C core antigen testing for diagnosis of hepatitis C virus infection: a systematic review and meta-analysis","volume":"165","author":"Freiman","year":"2016","journal-title":"Ann Intern Med"},{"key":"2020062607534775800_CIT0032","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1377\/hlthaff.2016.0296","article-title":"New hepatitis C drugs are very costly and unavailable to many state prisoners","volume":"35","author":"Beckman","year":"2016","journal-title":"Health Aff (Millwood)"},{"key":"2020062607534775800_CIT0033","volume-title":"Cost effectiveness in health and medicine","author":"Neumann","year":"2017","edition":"2"},{"key":"2020062607534775800_CIT0034","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.socscimed.2012.02.046","article-title":"Is travel-time to a specialist centre a risk factor for non-referral, non-attendance and loss to follow-up among patients with hepatitis C (HCV) infection?","volume":"75","author":"Astell-Burt","year":"2012","journal-title":"Soc Sci Med"},{"key":"2020062607534775800_CIT0035","author":"Department of Corrections Washington State"},{"key":"2020062607534775800_CIT0036","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1001\/jama.2018.15782","article-title":"Alternative state-level financing for hepatitis C treatment\u2014the \u201cNetflix model.\u201d","volume":"320","author":"Trusheim","year":"2018","journal-title":"JAMA"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciz383\/28955519\/ciz383.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/cid\/article-pdf\/70\/7\/1388\/33431650\/ciz383.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/cid\/article-pdf\/70\/7\/1388\/33431650\/ciz383.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,26]],"date-time":"2020-06-26T15:25:47Z","timestamp":1593185147000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/70\/7\/1388\/5490662"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,16]]},"references-count":36,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2019,5,16]]},"published-print":{"date-parts":[[2020,3,17]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciz383","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,4,1]]},"published":{"date-parts":[[2019,5,16]]}}}